Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of MRG004A in tissue factor-positive advanced or metastatic solid tumors
CTR20221675Phase 2Active
- Sponsor
- Hangzhou Miracogen
- Start
- Oct 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MRG004A in Nonhematologic neoplasms, sponsored by Hangzhou Miracogen. Started Oct 2022; status: active.
02
Drugs
MRG004A
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20221675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221675.